2024
How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice
Kumthekar A, Sanghavi N, Natu A, Danve A. How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice. Current Rheumatology Reports 2024, 26: 170-177. PMID: 38372873, DOI: 10.1007/s11926-024-01141-0.Peer-Reviewed Original ResearchBath Ankylosing Spondylitis Disease Activity IndexElectronic patient-reported outcome measuresDisease activity measuresAssessment of disease activityC-reactive proteinDisease activityAxial spondyloarthritisDisease activity of axial spondyloarthritisClinical practicePatient-Reported Outcomes Measurement Information SystemOutcomes Measurement Information SystemOutcome measuresAnkylosing Spondylitis Disease Activity IndexIntegration of electronic health recordsMonitoring of disease activitySymptoms of axSpATreatment of axSpA.Patient-reported outcome measuresMeasurement Information SystemAxSpA disease activityElectronic health recordsMonitoring disease activityDisease activity indexLong-term outcomesPatient-reported data
2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial
Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial. Clinical Rheumatology 2020, 40: 1331-1341. PMID: 32926247, DOI: 10.1007/s10067-020-05342-7.Peer-Reviewed Original ResearchConceptsHealth-related qualityDisease activityWeek 52Work Limitations QuestionnaireIntravenous golimumabWeeks 0Week 16Functioning outcomesEQ-5D-5L indexPlacebo-crossover groupProductivity loss scoresEffective treatment optionVisual analog scaleConclusionsIn patientsPlacebo groupSpondylitis QualityAdult patientsAnalog scaleEQ-VASWeek 28Treatment optionsProductivity outcomesWeek 8GolimumabHRQoL
2018
Complementary medicine for axial spondyloarthritis
Danve A, Deodhar A. Complementary medicine for axial spondyloarthritis. Current Opinion In Rheumatology 2018, 30: 310-318. PMID: 29634580, DOI: 10.1097/bor.0000000000000513.Peer-Reviewed Original ResearchConceptsCAM therapiesMind-body techniquesClinical trialsGood quality clinical trialsTrial of yogaStrong placebo effectMajority of patientsAlternative medicine (CAM) therapiesQuality clinical trialsManagement of axSpAUse of yogaDeep tissue massageAvailable scientific evidenceTui NaAdvanced diseaseDisease activityExercise programAxial spondyloarthritisFecal transplantTai ChiSide effectsPlacebo effectSmall studyComplementary medicineControl groupAB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis
Chock Y, Danve A, School of Medicine O, Petri M, Fu W. AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis. Annals Of The Rheumatic Diseases 2018, 77: 1425. DOI: 10.1136/annrheumdis-2018-eular.4524.Peer-Reviewed Original ResearchSystemic lupus erythematosusBody mass indexChronic kidney diseaseLow disease activityLupus nephritisSLE patientsDisease activityComplement levelsMass indexAvailable body mass indexBiopsy-proven lupus nephritisLow-grade inflammatory stateElevated body mass indexRetrospective cross-sectional studyFirst BMI measurementRisk of nephritisCategorical variablesHigher leptin levelsCross-sectional studyHigher complement levelsChi-square testLupus CohortCohort entryObese patientsACR criteria
2015
The ongoing quest for biomarkers in Ankylosing Spondylitis
Danve A, O'Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. International Journal Of Rheumatic Diseases 2015, 18: 826-834. PMID: 26469363, DOI: 10.1111/1756-185x.12779.Peer-Reviewed Original ResearchConceptsRadiographic progressionC-reactive proteinChronic inflammatory diseaseQuality of lifeDisease activityPotential clinical applicationsHLA-B27Ankylosing SpondylitisDiscovery of biomarkersInflammatory diseasesEarly diagnosisNew biomarkersSpondylitisBiomarkersDisease assessmentClinical applicationProgressionImmunopathogenesisTherapySymptomsDiseaseDiagnosisThe Role of 18F Fluorodeoxyglucose Positron Emission Tomography Scanning in the Diagnosis and Management of Systemic Vasculitis
Danve A, O'Dell J. The Role of 18F Fluorodeoxyglucose Positron Emission Tomography Scanning in the Diagnosis and Management of Systemic Vasculitis. International Journal Of Rheumatic Diseases 2015, 18: 714-724. PMID: 26177990, DOI: 10.1111/1756-185x.12713.Peer-Reviewed Original ResearchConceptsGiant cell arteritisPositron emission tomography scanningFDG-PETSystemic vasculitisTakayasu arteritisMagnetic resonance imagingEarly diagnosisFluorodeoxyglucose positron emission tomography scanningCranial giant cell arteritisTomography scanningBlood vesselsInvolved blood vesselsEnd-organ damageLarge vessel vasculitidesPrimary systemic vasculitisSmall vessel vasculitisNon-specific symptomsActive inflammatory cellsStandard imaging testPrediction of relapseDisease activityActive inflammationCell arteritisVessel vasculitisOrgan damageIL-17 Inhibition in Axial Spondyloarthritis
Danve A, Deodhar A. IL-17 Inhibition in Axial Spondyloarthritis. Current Treatment Options In Rheumatology 2015, 1: 221-230. DOI: 10.1007/s40674-015-0020-9.Peer-Reviewed Original ResearchIL-23/ILIL-17IL-23Monoclonal antibodiesExtra-articular manifestationsTNF-α blockadeIL-17 inhibitionIL-23 receptorQuality of lifeSignificant beneficial effectDisease activityProspective trialRadiographic progressionInhibitor medicationIL-12MRI scoresPhysical functionAxial spondyloarthritisClinical studiesP40 subunitAnimal modelsBeneficial effectsWestern populationsNovel optionSpondyloarthritis
2014
AB0677 Routine Assessment of Patient Index Data 3 Scores Correlate Well with Bath Ankylosing Spondylitis Disease Activity Index in the Assessment of Disease Activity and Monitoring Progression of Ankylosing Spondylitis
Danve A, Reddy A, Vakil-Gilani K, Dinno A, Deodhar A. AB0677 Routine Assessment of Patient Index Data 3 Scores Correlate Well with Bath Ankylosing Spondylitis Disease Activity Index in the Assessment of Disease Activity and Monitoring Progression of Ankylosing Spondylitis. Annals Of The Rheumatic Diseases 2014, 73: 1029. DOI: 10.1136/annrheumdis-2014-eular.1321.Peer-Reviewed Original ResearchBath Ankylosing Spondylitis Disease Activity IndexSpondylitis Disease Activity IndexDisease activity indexDisease activityRheumatoid arthritisRheumatic diseasesBaseline Bath Ankylosing Spondylitis Disease Activity IndexRoutine assessmentDisease Activity Score 28Patient Index Data 3Activity indexElectronic medical record searchPatient global assessmentMedical record searchRAPID3 scoresScore 28Disease durationPatient functionRheumatology practicePhysical functionRAPID3PatientsRecord searchGlobal assessmentBusy practiceAB0740 Comparative Study of Patients with Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis without Psoriasis
Danve A, Garg N, Reddy A, Ku J, Deodhar A. AB0740 Comparative Study of Patients with Peripheral Psoriatic Arthritis, Axial Psoriatic Arthritis and Axial Spondyloarthritis without Psoriasis. Annals Of The Rheumatic Diseases 2014, 73: 1048. DOI: 10.1136/annrheumdis-2014-eular.1322.Peer-Reviewed Original ResearchAxSpA patientsAxial involvementPsoriatic arthritisQuality of lifePeripheral arthritisAxSpA groupDisease characteristicsPeripheral diseaseExact testLong-term prospective studiesPeripheral psoriatic arthritisPrevalence of fibromyalgiaRAPID-3 scoresInflammatory bowel diseaseTerm prospective studiesPrevalence of depressionStatistical significanceAxial spondyloarthritis patientsFisher's exact testAxial psoriatic arthritisElectronic medical recordsMean ESRPsoriatic spondyloarthropathyDisease activityPsA patients